CGRP inhibitors for migraine prophylaxis: a safety review

References

• Olesen J, Steiner TJ. The international c1assification of headache disorders, 2nd edn (ICDH-II). J Neurol Neurosurg Psychiatry. 2004;75:808–811.
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38:1–211.
   PubMed Web of Science ®Google Scholar
• GBD2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the global burden of dise study 2016. Lancet Neurol. 2018;954:976.
   Google Scholar
• Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23:193–196.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med. 2007;13:39–44.
   PubMed Web of Science ®Google Scholar
• Villalón CM, Olesen J. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther. 2009;124:309–323.
   PubMed Web of Science ®Google Scholar
• Noseda R, Burstein R. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain. Pain. 2013;154(Suppl 1):S44–S53.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33:48–53.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attack therapies. Brain. 1994;117:427–434.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Goadsby PJ. Neuropeptides in migraine and cluster headache. Cephalalgia. 1994;14:320–327.
   PubMed Web of Science ®Google Scholar
• Fanciullacci M, Alessandri M, Figini M, et al. Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerine-induced cluster headache attack. Pain. 1995;60:119–123.
   PubMed Web of Science ®Google Scholar
• Asghar MS, Hansen AE, Kapijimpanga T, et al. Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers. Neurology. 2010;75:1520–1526.
   PubMed Web of Science ®Google Scholar
• Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia. 2002;22:54–61.
   PubMed Web of Science ®Google Scholar
• Hansen JM, Hauge AW, Olesen J, et al. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010;30:1179–1186.
   PubMed Web of Science ®Google Scholar
• de Vries T, Villalón CM, MaassenVanDenBrink A. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol Ther. 2020 [published online 2020 Mar 12]. doi:https://doi.org/10.1016/j.pharmthera.2020.107528.
   Google Scholar
• Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22:633–658.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Sprenger T. Current practice and future directions in the prevention and acute management of migraine. Neurol. 2010;9:285–298.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015;55(Suppl 2):103–122.
   PubMedGoogle Scholar
• Weatherall MW. The diagnosis and treatment of chronic migraine. Ther Adv Chronic Dis. 2015;6:115–123.
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Preventive migraine treatment. Neurol Clin. 2009;27:429–443.
   PubMed Web of Science ®Google Scholar
• Sun-Edelstein C, Rapoport AM. Update on the pharmacological treatment of chronic migraine. Curr Pain Headache Rep. 2016;20:6.
   PubMed Web of Science ®Google Scholar
• Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet. 2019;394:1765–1774.
   PubMed Web of Science ®Google Scholar
• Hoehlig K, Johnson KW, Pryazhnikov E, et al. A novel CGRP-neutralizing Spiegelmer attenuates neurogenic plasma protein extravasation. Br J Pharmacol. 2015;172:3086–3098.
   PubMed Web of Science ®Google Scholar
• Amgen Inc. Erenumab (Aimovig™): US prescribing information. [ cited 2020 Apr 11]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761077s000lbl.pdf
   Google Scholar
• Deen M, Correnti E, Kamm K, et al. Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain. 2017;18:96.
   PubMed Web of Science ®Google Scholar
• González-Hernández A, Marichal-Cancino BA, MaassenVanDenBrink A, et al. Side effects associated with current and prospective antimigraine pharmacotherapies. Expert Opin Drug Metab Toxicol. 2018;14:25–41.
   PubMed Web of Science ®Google Scholar
• Favoni V, Giani L, Al-Hassany L, et al. CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? J Headache Pain. 2019;20:27.
   PubMed Web of Science ®Google Scholar
• Gupta S, Nahas SJ, Peterlin BL. Chemical mediators of migraine: preclinical and clinical observations. Headache. 2011;51:1029–1045.
   PubMed Web of Science ®Google Scholar
• Rosenfeld MG, Mermod JJ, Amara SG, et al. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature. 1983;304:129–135.
   PubMed Web of Science ®Google Scholar
• Brain SD, Williams TJ, Tippins JR, et al. Calcitonin gene-related peptide is a potent vasodilator. Nature. 1985;313:54–56.
   PubMed Web of Science ®Google Scholar
• Hay DL, Garelja ML, Poyner DR, et al. Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR review 25. Br J Pharmacol. 2018;175:3–17.
   PubMed Web of Science ®Google Scholar
• Russell FA, King R, Smillie SJ, et al. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014;94:1099–1142.
   PubMed Web of Science ®Google Scholar
• Mulderry PK, Ghatei MA, Bishop AE, et al. Distribution and chromatographic characterisation of CGRP-like immunoreactivity in the brain and gut of the rat. Regul Pept. 1985;12:133–143.
   PubMedGoogle Scholar
• Hoffmann J, Wecker S, Neeb L, et al. Primary trigeminal afferents are the main source for stimulus-induced CGRP release into jugular vein blood and CSF. Cephalalgia. 2012;32:659–667.
   PubMed Web of Science ®Google Scholar
• Iyengar S, Johnson KW, Ossipow MH, et al. CGRP and the trigeminal system in migraine. Headache. 2019;59:659–681.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Ekman R, Jansen I, et al. Calcitonin gene-related peptide and cerebral blood vessels: distribution and vasomotor effects. J Cereb Blook Flow Metab. 1987;7:720–728.
   PubMed Web of Science ®Google Scholar
• Cady RK, Vause CV, Ho TW, et al. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache. 2009;49:1258–1266.
   PubMed Web of Science ®Google Scholar
• Russo AF, Kuburas A, Kaiser EA, et al. A potential preclinical migraine model: CGRP-sensitized mice. Mol Cell Pharmacol. 2009;1:264–270.
   PubMedGoogle Scholar
• Wattiez AS, Wang M, Russo AF. CGRP in animal models of migraine. Handb Exp Pharmacol. 2019;255:85–107.
   PubMedGoogle Scholar
• Arulmani U, Gupta S, MaassenVanDenBrink A, et al. Experimental migraine models and their relevance in migraine therapy. Cephalalgia. 2006;26:642–659.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Haanes KA, Warfvinge K, et al. CGRP as the target of new migraine therapies – successful translation from bench to clinic. Nat Rev Neurol. 2018;14:338–350.
   PubMed Web of Science ®Google Scholar
• Iovino M, Feifel U, Yong CL, et al. Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia. 2004;24:645–656.
   PubMed Web of Science ®Google Scholar
• Ho TW, Connor KM, Xhang Y, et al. Randomized controlled trials of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology. 2014;83:958–966.
   PubMed Web of Science ®Google Scholar
• Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011;31:712–722.
   PubMed Web of Science ®Google Scholar
• Diener HC, Barbanti P, Dahhlof C, et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011;3:573–584.
   Google Scholar
• Allergan plc. Allergan receives U.S. FDA approval for UBRELVY™ for the acute treatment of migraine with or without aura in adults. [ cited 2020 Apr 24]. Available from: https://www.prnewswire.com/news-releases/allergan-receives-us-fda-approval-for-ubrelvy-for-the-acute-treatment-of-migraine-with-or-without-aura-in-adults-300979082.html
   Google Scholar
• Biohaven Pharmaceutical Company Holding Ltd. Biohaven’s NURTEC™ ODT (rimegepant) receives FDA approval for the acute treatment of migraine in adults. [ cited 2020 Apr 6]. Available from: https://www.prnewswire.com/news-releases/biohavens-nurtec-odt-rimegepant-receives-fdaapproval-for-the-acute-treatment-of-migraine-in-adults-301013021.html
   Google Scholar
• NCT0372368. Efficacy and safety trial of rimegepant for migraine prevention in adults. [ cited 2020 Apr 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT03732638
   Google Scholar
• NCT02848326. Efficacy, safety, and tolerability of multiple dosing regimens of oral atogepant (AGN-241689) in episodic migraine prevention. [ cited 2020 Apr 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT02848326
   Google Scholar
• Allergan plc. Allergan’s oral CGRP receptor antagonist atogepant demonstrates robust efficacy and safety in episodic migraine prevention in a phase </Collab>2b/3 clinical trial. [ cited 2020 10 Apr]. Available from: https://www.prnewswire.com/news-releases/allergans-oral-cgrp-receptor-antagonist-atogepantdemonstrates-robust-efficacy-and-safety-in-episodic-migraine-prevention-in-a-phase-2b3-clinical-trial-300663770.html
   Google Scholar
• Martelletti P, Cipolla F, Capi M, et al. Atogepant. calcitonin gene-related peptide (CGRP) receptor antagonist, preventive treatment of migraine. Drugs Future. 2020 [ published online 2020 May]. DOI:https://doi.org/10.1358/dof.2020.45.5.3123467.
   Google Scholar
• NCT03855137. Efficacy, safety, and tolerability of atogepant for the prevention of chronic migraine. [ cited 2020 Apr 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT03855137
   Google Scholar
• Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014;34:114–125.
   PubMed Web of Science ®Google Scholar
• Croop R, Goadsby PJ, Stock DA, et al. Efcacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394:737–745.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381:142–149.
   PubMed Web of Science ®Google Scholar
• Biohaven Pharmaceutical Company Holding Ltd. Biohaven delivers positive phase 3 results with rimegepant zydis® orally dissolving tablet (ODT): rapid and lasting benefit for the acute treatment of migraine. [ cited 2020 Apr 6]. Available from: https://www.prnewswire.com/news-releases/biohaven-delivers-positivephase-3-results-with-rimegepant-zydis-orally-dissolving-tablet-odt-rapid-and-lasting-benefit-forthe-acute-treatment-of-migraine-300758762.html
   Google Scholar
• Rubio-Beltran E, Chan KY, Danser AJ, et al. Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries. Cephalalgia. 2020;40:357–366.
   PubMed Web of Science ®Google Scholar
• Sacco S, Bendtsen L, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine preventionPractice Guideline. . J Headache Pain. 2019;20:6.
   PubMed Web of Science ®Google Scholar
• Edvinsson JCA, Viganò A, Alekseeva A, et al. The fifth cranial nerve in headaches. J Headache Pain. 2020;00:65.
   Google Scholar
• Shi L, Lehto SG, Zhu DX, et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J Pharmacol Exp Ther. 2016;356:223–231.
   PubMed Web of Science ®Google Scholar
• Novartis. Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention. [ cited 2020 Apr 11] Available from: https://www.novartis.com/news/media-releases/novartis-and-amgen-announce-fda-approval-aimovigtm-erenumab-novel-treatment-developed-specifically-migraine-prevention
   Google Scholar
• Novartis. Novartis receives European licence for Aimovig®?(erenumab), the first treatment designed specifically for the prevention of migraine. [ cited 2020 Apr 11]. Available from: https://www.novartis.co.uk/news/media-releases/novartis-receives-european-licence-aimovigrverenumab-first-treatment-designed
   Google Scholar
• Sun H, Dodick DW, Silberstein S, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15:382–390.
   PubMed Web of Science ®Google Scholar
• Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:425–434.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Ashina M, Brandes JL, et al. ARISE: A phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026–1037.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of Erenumab for episodic migraine. N Engl J Med. 2017;377:2123–2132.
   PubMed Web of Science ®Google Scholar
• Ashina M, Goadsby PL, Reuter U, et al. Long-term safety and tolerability of erenumab: three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia. 2019;39:1455–1464.
   PubMed Web of Science ®Google Scholar
• Tepper SJ, Ashina M, Reuter U, et al. Long-term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week, open-label extension study. Cephalalgia. 2020;40:543–553.
   PubMed Web of Science ®Google Scholar
• Rubio-Beltrán E, Labastida-Ramírez A, Haanes KA, et al. Characterisation of vasodilatory responses in presence of the CGRP receptor antibody erenumab in human isolated arteries. Cephalalgia. 2019;39:1735–1744.
   PubMed Web of Science ®Google Scholar
• Haanes K, Chan KY, MaassenVanDenBrink A. Comment on “A second trigeminal CGRP receptor: function and expression of the AMY1 receptor”. Ann Clin Transl Neurol. 2016;3:307–308.
   PubMed Web of Science ®Google Scholar
• Walker CS, Eftekhari S, Bower RL, et al. A second trigeminal CGRP receptor: function and expression of the AMY1 receptor. Ann Clin Transl Neurol. 2015;2:595–608.
   PubMed Web of Science ®Google Scholar
• Lundbeck H, A S H. Lundbeck A/S. FDA approves Lundbeck’s Vyepti™ (eptinezumab-jjmr) – the first and only intravenous preventive treatment for migraine.[ cited 2020 Apr 10]. Available from: https://investor.lundbeck.com/news-releases/newsrelease-details/fda-approves-lundbecks-vyeptitm-eptinezumab-jjmr-first-and-only/
   Google Scholar
• Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014;13:1100–1107.
   PubMed Web of Science ®Google Scholar
• Ashina M, Saper J, Schaeffler BA, et al. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020. published online 2020 Feb 19. DOI:https://doi.org/10.1177/0333102420905132.
   Google Scholar
• Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine PROMISE 2. Neurology. 2020;94:e1365–e1377.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Escandon R, Bronson M, et al. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the phase 1 program. Cephalalgia. 2014;34:483–492.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Drug approval package: ajovy (fremanezumab-vfrm). Teva Pharmaceuticals USA, Inc; [ cited 2020 Apr 11]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761089Orig1s000TOC.cfm
   Google Scholar
• Teva Pharmaceutical Industries Ltd. Teva’s AJOVY® receives EU approval offering patients the first and only anti-CGRP treatment with both quarterly and monthly dosing for the prophylaxis of migraine in adults.[ cited 2020 Apr 14] Available from: https://www.tevapharm.com/news-and-media/latest-news/tevas-ajovy-receives-eu-approval-offering-patients-the-first-and-only-anti-cgrp-treatment-with-both-qua/
   Google Scholar
• Bigal ME, Dodick DW, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14:1081–1090.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;318:1999–2008.
   Google Scholar
• Bigal ME, Edvinsson L, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14:1091–1100.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377:2113–2122.
   PubMed Web of Science ®Google Scholar
• Cohen JM, Dodick DW, Yang R, et al. Fremanezumab as add-on treatment for patients treated with other migraine preventive medicines. Headache. 2017;57:1375–1384.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Walter S, Bronson M, et al. Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP. Cephalalgia. 2014;34:968–976.
   PubMed Web of Science ®Google Scholar
• Lionetto L, Curto M, Cisale GY, et al. Fremanezumab for the preventive treatment of migraine in adults. Expert Rev Clin Pharmacol. 2019;12:741–748.
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company. Lilly’s Emgality™ (galcanezumab-gnlm) receives U.S. FDA approval for the preventive treatment of migraine in adults. [ cited 2020 Apr 20] Available from: https://investor.lilly.com/news-releases/news-release-details/lillys-emgalitytm-galcanezumab-gnlm-receives-us-fda-approval
   Google Scholar
• European Medicines Agency. Emgality (galcanezumab). [ cited 2020 Apr 20]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/emgality
   Google Scholar
• European Medicines Agency. Emgality (galcanezumab). [ cited 2020 Apr 28]. Available from: https://www.ema.europa.eu/en/medicines/human/summaries-opinion/emgality
   Google Scholar
• Skljarevski V, Oakes TM, Zhang Q, et al. Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol. 2018;75:187–193.
   PubMed Web of Science ®Google Scholar
• Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75:1080–1088.
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38:1442–1454.
   PubMed Web of Science ®Google Scholar
• Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91:e2211–e2221.
   PubMed Web of Science ®Google Scholar
• Camporeale A, Kudrow D, Sides R, et al. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine. BMC Neurol. 2018;18:188.
   PubMed Web of Science ®Google Scholar
• Denekas T, Tröltzsch M, Vater A, et al. Inhibition of stimulated meningeal blood flow by a calcitonin gene-related peptide binding mirror-image RNA oligonucleotide. Br J Pharmacol. 2006;148:536–543.
   Google Scholar
• Peskar BM, Wong HC, Walsh JH, et al. A monoclonal antibody to calcitonin gene-related peptide abolishes capsaicin-induced gastroprotection. Eur J Pharmacol. 1993;250:201–203.
   PubMed Web of Science ®Google Scholar
• Reinshagen M, Flämig G, Ernst S, et al. Calcitonin gene-related peptide mediates the protective effect of sensory nerves in a model of colonic injury. J Pharmacol Exp Ther. 1998;286:657–661.
   PubMed Web of Science ®Google Scholar
• Bartho L, Koczan G, Maggi CA. Studies on the mechanism of the contractile action of rat calcitonin gene-related peptide and of capsaicin on the guinea-pig ileum: effect of hCGRP (8-37) and CGRP tachyphylaxis. Neuropeptides. 1993;25:325–329.
   PubMed Web of Science ®Google Scholar
• MaassenVanDenBrink A, Meijer J, Villalón CM, et al. Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol Sci. 2016;37:779–788.
   PubMed Web of Science ®Google Scholar
• Depre C, Antalik L, Starling A, et al. A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina. Headache. 2018;58:715–723.
   PubMed Web of Science ®Google Scholar
• MaassenVanDenBrink A, Rubio-Beltrán E, Duncker D, et al. Is CGRP receptor blockade cardiovascularly safe? Appropriate studies are needed. Headache. 2018;58:1257–1258.
   PubMed Web of Science ®Google Scholar
• Mulder IA, Li M, de Vries T, et al. Anti-migraine CGRP receptor antagonists worsen cerebral ischemic outcome in mice. Ann Neurol. 2020. published online 2020 June 25. DOI:https://doi.org/10.1002/ana.25831.
   Google Scholar
• Kaiser EA, Rea BJ, Kubiras A, et al. Anti-CGRP antibodies block CGRP-induced diarrhea in mice. Neuropeptides. 2017;64:95–99.
   PubMed Web of Science ®Google Scholar
• Smillie SJ, King R, Kodji X, et al. An ongoing role of a-calcitonin gene-related peptide as part of a protective network against hypertension, vascular hypertrophy, and oxidative stress. Hypertension. 2014;63:1056–1062.
   PubMed Web of Science ®Google Scholar
• Yallampalli C, Wimalawansa SJ. Calcitonin gene-related peptide (CGRP) is a mediator of vascular adaptations during hypertension in pregnancy. Trends Endocrinol Metab. 1998;9:113–117.
   PubMed Web of Science ®Google Scholar
• Schebesch KM, Herbst A, Bele S, et al. Calcitonin-gene related peptide and cerebral vasospasm. J Clin Neurosci. 2013;20:584–586.
   PubMed Web of Science ®Google Scholar
• Homma S, Kimura T, Sakai S, et al. Calcitonin gene-related peptide protects the myocardium from ischemia induced by endothelin-1: intravital microscopic observation and (31)P-MR spectroscopic studies. Life Sci. 2014;118:248–254.
   PubMed Web of Science ®Google Scholar
• IUPHAR/BPS Guide to PHARMACOLOGY. Calcitonin receptor. [ cited 2020 May 18]. Available from: https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=11
   Google Scholar
• Petersen KA, Birk S, Kitamura K, et al. Effect of adrenomedullin on the cerebral circulation: relevance to primary headache disorders. Cephalalgia. 2009;29:23–30.
   PubMed Web of Science ®Google Scholar
• Bailey R, Hay DL. Pharmacology of the human CGRP1 receptor in cos 7 cells. Peptides. 2006;27:1367–1375.
   PubMed Web of Science ®Google Scholar
• Giamberardino MA, Affaitati G, Martelletti P, et al. Impact of migraine on fibromyalgia symptoms. J Headache Pain. 2016;17:28.
   Web of Science ®Google Scholar
• Giamberardino MA, Costantini R. Challenging chronic migraine: targeting the CGRP receptor. Lancet Neurol. 2017;16:410–411.
   PubMed Web of Science ®Google Scholar
• Ornello R, Casalea A, Frattale I, et al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 2020;21:32.
   PubMed Web of Science ®Google Scholar
• Lambru G, Hill B, Murphy M, et al. A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain. 2020;21:61.
   PubMed Web of Science ®Google Scholar